Hence, instead of blocking downstream type 2 signature cytokines, the targeting of upstream alarmins, including IL-33 and TSLP has been proposed as an alternative treatment strategy for asthma and type 2 immunopathologies (14, 15). This evidence concerns the gene IL33 and asthma.